Skip to main content
. Author manuscript; available in PMC: 2016 Jun 7.
Published in final edited form as: Allergy. 2014 Apr 17;69(6):810–813. doi: 10.1111/all.12409

Fig. 1. KIT D816V allele burden in different WHO-subtype of mastocytosis and its impact on survival.

Fig. 1

(A) Highly significant differences in the KIT D816V allele burden were found between patients with cutaneous mastocytosis (CM), mastocytosis in the skin (MIS), indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and systemic mastocytosis with an associated hematologic non-mast cell lineage disease (SM-AHNMD) (P<0.001, Kruskal Wallis test). (B) Kaplan-Meier plot for overall survival of mastocytosis patients with a KIT D816V mutation burden <2% and patients with a KIT D816V burden of ≥ 2% at diagnosis. The difference in the probability of survival was significant (P=0.001).